Compare Direxion Daily TSLA Bull 2X Shares (TSLL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily TSLA Bull 2X Shares vs State Street SPDR S&P Biotech ETF — how do they compare? Direxion Daily TSLA Bull 2X Shares trades at $8.02, while State Street SPDR S&P Biotech ETF trades at $159.12. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| TSLL | XBI | |
|---|---|---|
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $23.03 | $164.28 |
52-Week Low | $6.74 | $88.79 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $8.05, down 1.95% on the day. The technical outlook is bearish, with moving averages signaling a downtrend and key support at $8. Recent news highlights the amplified volatility inherent in this leveraged Tesla ETF, as discussed by 24/7 Wall Street on July 31, 2026.
The outlook for TSLL is heavily dependent on the performance of Tesla stock, with significant risk from daily leverage decay and market volatility. Investment opportunity exists for those betting on short-term Tesla gains, but the structure poses substantial risk of loss even if Tesla's price increases over the long term.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
